Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Campus Vienna Biocenter - Progress on Alzheimer’s Vaccine

16.09.2005


An innovative vaccination can significantly reduce deposits of the substances in the brain responsible for causing Alzheimer’s disease. This result was disclosed today by Affiris GmbH, a company located at the Campus Vienna Biocenter, Austria. The rapid progress during the pre-clinical development phase has already enabled the Vienna-based company, although having operated only since April 2004, to plan clinical trials for 2006, and thus proves the international competitiveness of the Campus Vienna Biocenter.



Beta-amyloids are pathological fragments of a normal brain protein. They are responsible for the development of Alzheimer’s disease, as they cause the death of brain cells. Amyloid fragments are found in large amounts in the cerebral fluid of Alzheimer patients. Deposits are formed in the brain over the years, thus creating the plaque structures typical of Alzheimer’s disease. It has not yet been completely clarified whether plaque formation or the soluble beta-amyloids are the causative agents for Alzheimer’s disease.

Tailor-made Vaccine


The Vienna-based company Affiris is now reporting that it has succeeded in significantly reducing Alzheimer plaques by at least two-thirds in pre-clinical models by means of an innovative vaccine. CEO Dr. Walter Schmidt explains the important feature of the vaccination strategy: "Alzheimer’s is caused by a fragment of one of the ubiquitous proteins of cerebral cells. If one wants to combat Alzheimer immunologically it is essential to generate antibodies which are targeted against the beta-amyloids, but which leave the normal constituent of the cerebral cells unharmed, since the latter would induce an autoimmune disease. In keeping with this, Affiris´ vaccine approach has been shown to be highly specific for beta amyloids and not to react with the normal constituent of cerebral cells."

Thus, the Affiris approach not only avoids an autoimmune disease, but also offers the advantage of targeting simultaneously both the plaques and the soluble beta-amyloid fraction. Therefore, whether the soluble or plaque forms - or both - are responsible for causing the disease is not ultimately crucial for the vaccine’s success. The additional proof that the vaccine induces antibodies, which are active against plaques in human tissue samples, and the first data collected on the toxicology profile have further contributed to built a secure basis for Affiris to schedule the first trials on patients for 2006.

Biotech with Economics

Beside its scientific success Affiris also boasts important economic advantages: low costs and short manufacturing times for its vaccine. In the words of Dr. Schmidt: "Our substances are produced at low costs and a building-block system is used to form the vaccine. The effective component is synthetically manufactured and combined with a carrier substance isolated from natural resources. Both together form the actual vaccine and a standard adjuvant is added to strengthen the immune response."

The fact that the management has taken these important economic aspects into consideration from the very beginning is also due to the comprehensive biotech experiences at the Campus Vienna Biocenter. After all, numerous biotech companies and research institutes are situated at the Campus Vienna Biocenter, in addition to the FH Campus Wien (biotechnology), the Life Science Departments of the University of Vienna and the Medical University of Vienna, all sharing both resources and experiences and thus contributing to the international success of this location.

About AFFiRiS (September 2005):

AFFiRiS develops peptide-based vaccines for the treatment of Alzheimer’s disease and atherosclerosis. The company has established platform technologies and registered seven patents. 12 employees work in a 6,500 sqf rented laboratory facility on the Campus Vienna Biocenter.

About the Campus Vienna Biocenter (September 2005):

The Campus Vienna Biocenter is one of the largest R&D clusters in Austria with approx. 1,000 scientists from 40 nations at 16 organisations. Academic departments (University of Vienna, Medical University of Vienna, subsumed in the Max F. Perutz Laboratories), private research institutes (IMP - Institute of Molecular Pathology) and institutes of the Austrian Academy of Sciences (IMBA - Institute of Molecular Biotechnology, GMI - Gregor Mendel Institute) are also located here along with commercial R&D companies, service companies and training course centres.

Till C. Jelitto | alfa
Further information:
http://www.prd.at
http://www.affiris.com
http://www.viennabiocenter.com

More articles from Health and Medicine:

nachricht World first: Massive thrombosis removed during early pregnancy
20.07.2017 | Universitätsspital Bern

nachricht Therapy of preterm birth in sight?
19.07.2017 | Universitätsspital Bern

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Manipulating Electron Spins Without Loss of Information

Physicists have developed a new technique that uses electrical voltages to control the electron spin on a chip. The newly-developed method provides protection from spin decay, meaning that the contained information can be maintained and transmitted over comparatively large distances, as has been demonstrated by a team from the University of Basel’s Department of Physics and the Swiss Nanoscience Institute. The results have been published in Physical Review X.

For several years, researchers have been trying to use the spin of an electron to store and transmit information. The spin of each electron is always coupled...

Im Focus: The proton precisely weighted

What is the mass of a proton? Scientists from Germany and Japan successfully did an important step towards the most exact knowledge of this fundamental constant. By means of precision measurements on a single proton, they could improve the precision by a factor of three and also correct the existing value.

To determine the mass of a single proton still more accurate – a group of physicists led by Klaus Blaum and Sven Sturm of the Max Planck Institute for Nuclear...

Im Focus: On the way to a biological alternative

A bacterial enzyme enables reactions that open up alternatives to key industrial chemical processes

The research team of Prof. Dr. Oliver Einsle at the University of Freiburg's Institute of Biochemistry has long been exploring the functioning of nitrogenase....

Im Focus: The 1 trillion tonne iceberg

Larsen C Ice Shelf rift finally breaks through

A one trillion tonne iceberg - one of the biggest ever recorded -- has calved away from the Larsen C Ice Shelf in Antarctica, after a rift in the ice,...

Im Focus: Laser-cooled ions contribute to better understanding of friction

Physics supports biology: Researchers from PTB have developed a model system to investigate friction phenomena with atomic precision

Friction: what you want from car brakes, otherwise rather a nuisance. In any case, it is useful to know as precisely as possible how friction phenomena arise –...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

»We are bringing Additive Manufacturing to SMEs«

19.07.2017 | Event News

The technology with a feel for feelings

12.07.2017 | Event News

Leipzig HTP-Forum discusses "hydrothermal processes" as a key technology for a biobased economy

12.07.2017 | Event News

 
Latest News

Researchers create new technique for manipulating polarization of terahertz radiation

20.07.2017 | Information Technology

High-tech sensing illuminates concrete stress testing

20.07.2017 | Materials Sciences

First direct observation and measurement of ultra-fast moving vortices in superconductors

20.07.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>